Systematic review with meta-analysis on transplantation for alcohol-related liver disease: Very low evidence of improved outcomes

Table 1 Details of included studies and cohort baseline characteristics

Study	Place	Study design	Transplant					No-transplant
			n (%)	Age1 (SD or range)	Male sex n (%)	CTP1 (SD or range)	MELD (SD or range)	n (%)	Age1 (SD or range)	Male sex n (%)	CTP1 (SD or range)	MELD (SD or range)
Gish et al[24]	United States	P, C	29 (62)	472	30 (64)2	12 (9-15)2		14 (30)	472	30 (64)2	13 (9-15)2
Anand et al [22]	United Kingdom	R, C	39 (28)	48 (37-69)	34 (87)	113		94 (69)	51 (30-71)3	67 (74)	113
Poynard et al [25]	France	R, CC	169 (50)	47 (39-55)	NS	9 (5-15)3		169 (50)	47 (39-54)	NS	9 (5-15)3
Veldt et al[26]	France	P, C	2 (3)	59 (37-82)2	47 (64)2	11 (10-15)2		72 (97)	59 (37-82)2	47 (64)2	11 (10-15)2
DiMartino et al[23]	France	P, RCT	60 (50)	502	92 (77)2	8.22		60 (50)	502	92 (77)2	8.22
Immordino et al[20]	Germany	R, C	110 (45)	53 (30-68)	95 (86)	10 (6-13)	14 (4-35)	113 (46)	50 (33-64)	64 (57)	6.5 (5-13)	12 (6-40)
Alvarez et al [21]	Spain	P, C	5 (3)	< 65	NS	> 8	14 (13-15)2	156 (95)	56 (54-58)2	135 (82)2	9 (8-9)2	14 (13-15)2
Mathurin et al[18]	France	P, CC	26 (27)	47 (35-61)	15 (58)	NS	30 (22-47)	69 (73)	52 (47-54)	41 (59)	NS	NS
Im et al[19]	United States	P, CC	9 (10)	41 (30-60)	5 (55)	NS	39 (27-42)	79 (84)	48 (26-68)2	54 (57)2	NS	31 (16-52)2
Onishi et al[27]	Japan	R,	7 (7)	44 (28-51)	4 (57)	10.1(2)2	NS4	50 (75)	52 (31-69)	37 (74)	10.1 (2)2	NS4

¹Median values used if both mean and median were reported;

²Value is for the entire study population (both transplant and no-transplant);

³Calculated as the weighted average;

⁴Mean model for end-stage liver disease reported as 1.9 for the entire study population was omitted given concern for publication error.

P: Prospective; R: Retrospective; C: Cohort; CC: Case-control; RCT: Randomized controlled trial; CTP: Child-Turcotte-Pugh score; MELD: Model for end-stage liver disease; NS: Not specified.